Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 10/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6543759 | 0.84 | BDKRB1 (0.48) | BDKRB1KDM4EALDH1A1HPGDCRHBP | |
| SCHEMBL6542903 | 0.81 | ALDH1A1 (0.58) | BDKRB1KDM4EALDH1A1HPGDKDR | |
| SCHEMBL5871444 | 0.79 | PKM (0.58) | BDKRB1KDM4EALDH1A1HPGDCRHBP | |
| SCHEMBL18071001 | 0.78 | MAPT (0.65) | BDKRB1KDM4EALDH1A1MAPTKDR | |
| SCHEMBL7823349 | 0.78 | KDR (0.60) | BDKRB1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL6542710 | 0.78 | KDR (0.62) | BDKRB1ALDH1A1KDR | |
| SCHEMBL6543887 | 0.78 | BDKRB1 (0.48) | BDKRB1KDM4EALDH1A1HPGDCRHBP | |
| Hydrochloric Acid SCHEMBL7832291 | 0.77 | KDR (0.59) | BDKRB1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL6542940 | 0.77 | CHEK1 (0.50) | KDR | |
| SCHEMBL11492008 | 0.76 | KDM4E (0.54) | BDKRB1KDM4EALDH1A1HPGDCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | FLT4, KDR, FLT1 | BDKRB1 1372/4885KDM4E 831/4885ALDH1A1 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.